However, there is an enormous body of evidence which demonstrates that the availability and function of TβRII is crucial determinants of TGF-β signaling and aberrant TGF-β responses are frequent in human diseases, such as cancer, fibrosis, inflammation, and cardiovascular disease. The gene discussed is TGFBR2; the disease is cancer.